Diffuse large B-cell lymphoma: current treatment approaches
- PMID: 22730604
Diffuse large B-cell lymphoma: current treatment approaches
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoid malignancy. While a series of trials support R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone, plus rituximab)-21 as the standard of care for all patients, DLBCL has substantial biological and clinical heterogeneity, leading to marked differences in outcomes for disease subgroups. We examine clinical, biological, and functional imaging techniques for risk-stratifying patients, and we review approaches for dose intensification in the rituximab era that are aimed at improving outcomes for poor-risk patients. Together, the results achieved with these measures indicate no particular benefit for administering R-CHOP-14 vs R-CHOP-21 in older or younger patients with DLBCL, highlight opportunities for future studies of young patients with high-risk DLBCL, and suggest the promise of biologic risk stratification. Such approaches will provide key opportunities for further advances in the treatment of DLBCL, given that chemotherapy intensification appears to provide limited additional benefits over the current standard of care.
Similar articles
-
Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.Am J Hematol. 2013 May;88(5):400-5. doi: 10.1002/ajh.23423. Epub 2013 Mar 19. Am J Hematol. 2013. PMID: 23423884
-
Improving outcomes for patients with diffuse large B-cell lymphoma.CA Cancer J Clin. 2010 Nov-Dec;60(6):393-408. doi: 10.3322/caac.20087. Epub 2010 Oct 28. CA Cancer J Clin. 2010. PMID: 21030533 Review.
-
Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era.Ann Hematol. 2013 Nov;92(11):1495-501. doi: 10.1007/s00277-013-1789-y. Epub 2013 May 28. Ann Hematol. 2013. PMID: 23712292
-
Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.Ann Hematol. 2012 Nov;91(11):1721-9. doi: 10.1007/s00277-012-1507-1. Epub 2012 Jun 26. Ann Hematol. 2012. PMID: 22733613
-
Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective.Oncology (Williston Park). 2005 Apr;19(4 Suppl 1):26-34. Oncology (Williston Park). 2005. PMID: 15934515 Review.
Cited by
-
Treatment of adolescents with aggressive B-cell malignancies: the pediatric experience.Curr Hematol Malig Rep. 2013 Sep;8(3):226-35. doi: 10.1007/s11899-013-0166-1. Curr Hematol Malig Rep. 2013. PMID: 23812872 Review.
-
Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.J Hematol Oncol. 2015 Jun 14;8:70. doi: 10.1186/s13045-015-0168-7. J Hematol Oncol. 2015. PMID: 26071053 Free PMC article.
-
Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL.Cancer Res. 2013 Aug 15;73(16):5029-39. doi: 10.1158/0008-5472.CAN-12-3546. Epub 2013 Jun 19. Cancer Res. 2013. PMID: 23783577 Free PMC article.
-
Testis specific gene expression drives disease progression and Rituximab resistance in lymphoma.EMBO Mol Med. 2013 Aug;5(8):1149-50. doi: 10.1002/emmm.201303018. EMBO Mol Med. 2013. PMID: 23918227 Free PMC article. No abstract available.
-
Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter.J Gene Med. 2014 Jan-Feb;16(1-2):11-27. doi: 10.1002/jgm.2754. J Gene Med. 2014. PMID: 24436117 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
